For research use only. Not for therapeutic Use.
Tregalizumab（Cat No.:I042251）is a monoclonal antibody designed to enhance the function and expansion of regulatory T cells (Tregs), a subset of immune cells that play a crucial role in maintaining immune tolerance and preventing excessive inflammation. By targeting and activating the CD28 receptor on Tregs, Tregalizumab aims to increase their ability to suppress immune responses, potentially offering therapeutic benefits for autoimmune diseases, graft-versus-host disease, and inflammatory conditions. Clinical trials are exploring Tregalizumab’s safety and efficacy, particularly in diseases where immune regulation is impaired, to provide a novel approach to immune modulation and treatment.
| CAS Number | 1207446-68-1 |
| Purity | ≥95% |
